Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients
New math shows vaccine benefits in cancer care might be overstated
This narrative review and target trial emulation examines 3-year overall survival in cancer patients receiving COVID-19 vaccines versus thos…
A new look at the data reveals that timing errors made the vaccine look more powerful than it actually is for cancer patients.
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Meta-analysis of real-world studies associates COVID-19 vaccination with improved survival in cancer patients on ICIs
Cancer Patients Live Longer After COVID Shots
This meta-analysis of real-world studies evaluated 4,929 cancer patients receiving immune checkpoint inhibitors to assess COVID-19 vaccinati…
It started with a question doctors couldn’t answer: *Should patients on powerful cancer drugs get the COVID vaccine?* Some worried the immun…
Review of multi-omics technologies supporting immune checkpoint inhibitor use in cancer patients
New Data Helps Doctors Pick Better Cancer Treatments
This review examines the application of multi-omics technologies within cancer patients treated with immune checkpoint inhibitors.
Using many types of medical data helps doctors choose the right cancer drugs for each person.
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Mini-review discusses combination regimens built on immune checkpoint inhibitors and their associated immune-related adverse events
How Doctors Are Learning to Stop Cancer Therapy From Backfiring
This mini-review examines combination regimens built on immune checkpoint inhibitors (ICIs).
This research gives doctors a roadmap to predict and prevent dangerous side effects from powerful cancer treatments.
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.